HemoShear, Takeda in liver disease deal
HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive undisclosed upfront payments and R&D funding and is eligible for $470 million in milestones, plus royalties.
HemoShear Head of Innovation Brian Wamhoff told BioCentury the partnership has three aims -- to...
Read the full 272 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$35 USD
